Cellular and Molecular Actions of Methylene Blue in the Nervous System

被引:332
作者
Oz, Murat [1 ,2 ]
Lorke, Dietrich E. [3 ]
Hasan, Mohammed [2 ]
Petroianu, George A. [2 ]
机构
[1] NIDA, Integrat Neurosci Sect, Intramural Res Program, NIH,DHHS, Baltimore, MD 21224 USA
[2] UAE Univ, Dept Pharmacol, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
[3] UAE Univ, Dept Anat, Fac Med & Hlth Sci, Al Ain, U Arab Emirates
关键词
methylene blue; nervous system; phenothiazines; NITRIC-OXIDE SYNTHASE; PROLONGED POSTOPERATIVE DISORIENTATION; MONOAMINE-OXIDASE; IFOSFAMIDE ENCEPHALOPATHY; INTRATHECAL INJECTION; BETA OLIGOMERIZATION; PHOTODYNAMIC THERAPY; SEROTONIN TOXICITY; PARATHYROID-GLANDS; PROSTAGLANDIN E(2);
D O I
10.1002/med.20177
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Methylene Blue (MB), following its introduction to biology in the 19th century by Ehrlich, has found uses in various areas of medicine and biology. At present, MB is the first line of treatment in methemoglobinemias, is used frequently in the treatment of ifosfamide-induced encephalopathy, and is routinely employed as a diagnostic tool in surgical procedures. Furthermore, recent studies suggest that MB has beneficial effects in Alzheimer's disease and memory improvement. Although the modulation of the cGMP pathway is considered the most significant effect of MB, mediating its pharmacological actions, recent studies indicate that it has multiple cellular and molecular targets. In the majority of cases, biological effects and clinical applications of MB are dictated by its unique physicochemical properties including its planar structure, redox chemistry, ionic charges, and light spectrum characteristics. In this review article, these physicochemical features and the actions of MB on multiple cellular and molecular targets are discussed with regard to their relevance to the nervous system. (C) 2009 Wiley Periodicals, Inc. Med Res Rev, 31, No. 1, 93-117, 2010
引用
收藏
页码:93 / 117
页数:25
相关论文
共 238 条
[1]   Methylene blue is a muscarinic antagonist in cardiac myocytes [J].
AbiGerges, N ;
Eschenhagen, T ;
HoveMadsen, L ;
Fischmeister, R ;
Mery, PF .
MOLECULAR PHARMACOLOGY, 1997, 52 (03) :482-490
[2]  
Aeschlimann C, 1996, DRUG METAB DISPOS, V24, P1336
[3]   Ifosfamide encephalopathy [J].
Ajithkumar, T. ;
Parkinson, C. ;
Shamshad, F. ;
Murray, P. .
CLINICAL ONCOLOGY, 2007, 19 (02) :108-114
[4]   Methylene blue: Dangerous dye for neonates [J].
Albert, M ;
Lessin, MS ;
Gilchrist, BF .
JOURNAL OF PEDIATRIC SURGERY, 2003, 38 (08) :1244-1245
[5]   Ifosfamide neuropsychiatric toxicity in patients with cancer [J].
Alici-Evcimen, Yesne ;
Breitbart, William S. .
PSYCHO-ONCOLOGY, 2007, 16 (10) :956-960
[6]   Phenothiazines: potential management of Creutzfeldt-Jacob disease and its variants [J].
Amaral, L ;
Kristiansen, JE .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (05) :411-417
[7]  
[Anonymous], NATL TOXICOL PROGRAM
[8]   QUADRIPLEGIA AFTER INTRATHECAL INJECTION OF METHYLENE BLUE [J].
ARIEFF, AJ ;
PYZIK, SW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1960, 173 (07) :794-796
[9]   SIMULATION OF NA CHANNEL INACTIVATION BY THIAZIN DYES [J].
ARMSTRONG, CM ;
CROOP, RS .
JOURNAL OF GENERAL PHYSIOLOGY, 1982, 80 (05) :641-662
[10]   Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways [J].
Atamna, Hani ;
Nguyen, Andy ;
Schultz, Carla ;
Boyle, Kathleen ;
Newberry, Justin ;
Kato, Hiroyuki ;
Ames, Bruce N. .
FASEB JOURNAL, 2008, 22 (03) :703-712